Contact:
4008465777
-
About Us
News & Events
-
02-07
Tonghua Dongbao 2022 results: Insulin sales continue to grow
On February 6, 2023, Tonghua Dongbao Pharmaceutical Co., Ltd. (stock code: 600867, hereinafter referred to as "Tonghua Dongbao" or the "Company") released its financial results for 2022. Revenue is es...
-
02-02
Tonghua Dongbao's application of human insulin injection accepted by EMA
On February 1, 2023, Tonghua Dongbao Pharmaceutical Co., Ltd. ("the Company" or "Tonghua Dongbao") and Rechon Life Science AB ("Rechon") announced that the marketing authorization application (MAA) fo...
-
01-18
Tonghua Dongbao's Phase I clinical trial on its URAT1 inhibitor (THDBH130 Tablets) meets primary endpoint
Dongbao Zixing (Hangzhou) Biopharmaceutical Co., Ltd., a wholly owned subsidiary of Tonghua Dongbao Pharmaceutical Co., Ltd. ("the Company" or "Tonghua Dongbao"), recently completed a Phase I pivotal ...
-
01-17
Tonghua Dongbao announces NMPA acceptance of its clinical trial application for dual GLP-1/GIP receptor agonist (THDBH121 injection)
Recently, Dongbao Zixing (Hangzhou) Biopharmaceutical Co., Ltd. ("Dongbao Zixing"), a wholly owned subsidiary of Tonghua Dongbao Pharmaceutical Co., Ltd. (the "Company" or "Tonghua Dongbao") received ...
-
12-30
Tonghua Dongbao: Phase I clinical trial on the ultra-rapid-acting insulin lispro injection meets primary endpoint
Tonghua Dongbao Pharmaceutical Co., Ltd. (the "Company" or "Tonghua Dongbao") has recently completed a Phase I pivotal clinical trial on the BC Lispro (THDB0206), an ultra-rapid-acting insulin lispro ...
-
12-23
Tonghua Dongbao: Clinical trial application for THDBH151 Tablets approved
Recently, Dongbao Zixing (Hangzhou) Biopharmaceutical Co., Ltd. (“Dongbao Zixing”), a wholly-owned subsidiary of Tonghua Dongbao Pharmaceutical Co., Ltd. (the “Company” or “Tonghua Dongbao”) rec...